CCL5 and breast cancer: Zoledronic acid (ZA) [72], as well as PEGylated nanoparticles (NPs) encapsulating ZA [73], decreased both CCL5 and IL-6 secretion by MSCs, suggesting that ZA may exert antitumor activity by affecting the ability of MSCs to interact with breast cancer cells.